Cytochrome P450-activated prodrugs

Future Medicinal Chemistry

Volumn 5, Issue 2, 2013, Pages 213-228

  De Montellano, Paul R Ortiz ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BANOXANTRONE; BENZOTHIAZOLE DERIVATIVE; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DACARBAZINE; DUOCARMYCIN A; FLUTAMIDE; IFOSFAMIDE; LORATADINE; LOSARTAN; NABUMETONE; PAFURAMIDINE; PR 104; PRADEFOVIR; PRASUGREL; PROCARBAZINE; PRODRUG; TAMOXIFEN; TEGAFUR; TERFENADINE; TH 302; TICLOPIDINE; UNCLASSIFIED DRUG;

BIOSYNTHESIS; DRUG ACTIVATION; HUMAN; LIVER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; PRODRUGS;

EID: 84873281965     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.197     Document Type: Review

References (105)

1. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem. Biophys. Res. Commun. 152, 411-416 (1988).
2. Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm. Drug Dispos. 13, 445-460 (1992).
3. Srinivasan V, Wielbo D, Tebbett IR. Analgesis effects of codeine-6-glucuronide after intravenous administration. Eur. J. Pain 1, 185-190 (1997). (Pubitemid 127675874)
4. Vree TB, Van Dongren RT, Koopman- Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int. J. Clin. Pract. 54, 395-398 (2000). (Pubitemid 30604052)
5. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics 44, 515-520 (2003). (Pubitemid 37352231)
6. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (2006). (Pubitemid 44223697)
7. Kelly LE, Rieder M, van den Anker J et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 129, e1343-e1347 (2012).
8. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255-270 (2008). (Pubitemid 351324639)
9. Janin YL. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479-2513 (2007). (Pubitemid 46367698)
10. Guengerich FP. Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry. Ortiz de Montellano PR (Ed.). Kluwer/Plenum/ Elsevier, NY, USA, 377-530 (2005).
11. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
12. Rivera SP, Wang F, Saarikoski ST et al. A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of P4502S1 by both dioxin and hypoxia. J. Biol. Chem. 282, 10881-10893 (2007). (Pubitemid 47100738)
13. Downie D, McFadyen MCE, Rooney PH et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 11, 7369-7375 (2005). (Pubitemid 41507696)
14. Karlgren M, Gomez A, Stark K et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341, 451-458 (2006). (Pubitemid 43152125)
15. Wijnen PA, O den Buijsch RA, Drent M et al. The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment. Pharmacol. Ther. 26(Suppl. 2), 211-219 (2007). (Pubitemid 350233335)
16. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007). (Pubitemid 350116943)
17. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28, 1203-1253 (1998). (Pubitemid 29017141)
18. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J. Biochem. Mol. Toxicol. 21, 176-181 (2007). (Pubitemid 350194377)
19. Ortiz de Montellano PR, De Voss JJ. Substrate oxidation by cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry. Ortiz de Montellano PR (Ed.). Springer, NY, USA, 183-245 (2005).
20. Iyanagi T, Xia C, Kim JP. NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family. Arch. Biochem. Biophys. 528, 72-89 (2012).
21. Druckrey H. Experimentelle grundlagen der chemotherapie des krebses. Dtsch. Med. Wochenschr. 77, 1534-1537 (1952).
22. Brock N. The history of the oxazaphorphorine cytostatics. Cancer 78, 542-547 (1995).
23. Friedman OM, Myles A, Colvin M. Cyclophosphamide and phosphoramide mustards. Adv. Cancer Chemother. 1, 143-204 (1979).
24. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. 65(Suppl. 3), 89-95 (1981). (Pubitemid 13248878)
25. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37, 301-355 (1988).
26. Bunting KD, Townsend AJ. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 271, 11891-11896 (1996).
27. Mace JR, Keohan ML, Bernardy H et al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin. Cancer Res. 9, 5829-5834 (2003). (Pubitemid 38018064)
28. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos. 27, 655-666 (1999). (Pubitemid 29252439)
29. Nguyen T, Tychopoulos M, Bichat F et al. Improvement of cyclophosphamide activation by CY2B6 mutants: from in silico to ex vivo. Mol. Pharmacol. 73, 1122-1133 (2008). (Pubitemid 351439194)
30. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev. 31, 503-522 (1999). (Pubitemid 29222675)
31. Legha SS. Current therapy for malignant melanoma. Semin. Oncol. 16, 34-44 (1989). (Pubitemid 19086389)
32. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol. Res. 56, 275-287 (2007). (Pubitemid 47488901)
33. Kolar GF, Maurer M, Wildschütte M. 5-(3-Hydroxymethyl-3-methyl-1- triazeno imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno) imidazole-4- carboxamide (DIC, DTIC NSC-45388). Cancer Lett. 10, 235-241 (1980). (Pubitemid 11233270)
34. Meer L, Janzer RC, Kleihues P, Kolar GF. In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1- triazeno)imidazole-4- carboxamide (DTIC). Biochem. Pharmacol. 35, 3243-3247 (1986). (Pubitemid 16001430)
35. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2 and CYP2E1. Clin. Cancer Res. 5, 2192-2197 (1999). (Pubitemid 29399277)
36. Lewis BC, Mackenzie PI, Miners JO. Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine. Mol. Pharmacol. 80, 879-888 (2011).
37. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6, 2585-2597 (2000). (Pubitemid 30482092)
38. Swaffar DS, Horstman MG, Jaw J et al. Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Cancer Res. 49, 2442-2447 (1989). (Pubitemid 19125576)
39. Cummings SW, Guengerich FP, Prough RA. The characterization of N-isopropyl-p-hydroxymethylbenzamide formed during the oxidative metabolism of azo-procarbazine. Drug Metab. Dispos. 10, 459-464 (1982). (Pubitemid 12030676)
40. Weinkam RJ, Shiba DA. Metabolic activation of procarbazine. Life Sci. 22, 937-946 (1978). (Pubitemid 8314362)
41. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25, 1679-1691 (2006).
42. Au JL, Sadee W. The pharmacology of Ftorafur (R,S-1-(tetrahydro-2- furanyl)-5- fluorouracil). Recent Results Cancer Res. 76, 100-114 (1981).
43. Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56, 53-102 (2004). (Pubitemid 38314580)
44. Komatsu T, Yamazaki H, Shimada N et al. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin. Cancer Res. 7, 675-681 (2001). (Pubitemid 32707994)
45. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochrome P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 28, 1457-1463 (2000).
46. Ikeda K, Yoshisue K, Matsushima E et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin. Cancer Res. 6, 4409-4415 (2000).
47. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens) structure-activity relationships. Curr. Med. Chem. 7(2), 211-247 (2000). (Pubitemid 30396447)
48. Katchen B, Buxbaum S. Disposition of a new, nonsteroid, antiandrogen, a,a,a-trifluoro-2- methyl-4́-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. J. Clin. Endocrinol. Metab. 41, 373-379 (1975).
49. Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab. Dispos. 25, 1298-1303 (1997). (Pubitemid 27490675)
50. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Therap. 296, 537-541 (2001). (Pubitemid 32112483)
51. Morris JJ, Hughes LR, Glen AT, Taylor PJ. Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J. Med. Chem. 34, 447-455. (1991).
52. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sewuential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A4 and CYP2D6. J. Pharmacol. Exp. Therap. 310, 1062-1075 (2004). (Pubitemid 39108928)
53. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphism and the impact on tamoxifen therapy. J. Pharm. Sci. 96, 2224-2231 (2007). (Pubitemid 47477881)
54. Boger DL, Johnson DS. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl Acad. Sci. USA 92, 3642-3649 (1995).
55. Pors K, Loadman PM, Shnyder SD et al. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem. Commun. 47, 12062-12064 (2011).
56. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. 41, 297-316 (2001). (Pubitemid 32390115)
57. Jiang J, Chen C, Card JW et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65, 4707-4715 (2005). (Pubitemid 40740807)
58. Rieger MA, Ebner R, Bell DR et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 64, 2357-2364 (2004). (Pubitemid 38528668)
59. Downie D, McFadyen MCE, Rooney PH et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 11, 7369-7375 (2005). (Pubitemid 41507696)
60. Saarikosi ST, Wikman HA, Smith G, Wolff CHJ, Husgafvel-Pursiainen K. Localization of cytochrome CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J. Histochem. Cytochem. 53, 549-556 (2005). (Pubitemid 40593968)
61. Mortimer CG, Wells G, Crochard J-P et al. Antitumor benzothiazoles. 26. 2-(3,4-dimethoxyphenyl)-5- fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzo-thiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J. Med. Chem. 49, 179-185 (2006). (Pubitemid 43077331)
62. Brantley E, Trapani V, Alley MC et al. Fluorinated 2-(4-amino-3- methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cell lines. Drug Metab. Dispos. 32, 1392-1401 (2004). (Pubitemid 39564559)
63. Tan BS, Tiong KH, Muruhadas A et al. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5- fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol. Cancer Ther. 10, 1982-1992 (2011).
64. Wang K, Guengerich FP. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by hiuman cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1. Chem. Res. Toxicol. 25, 1740-1751 (2012).
65. Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56, 53-102 (2004). (Pubitemid 38314580)
66. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab. Rev. 34, 581-592 (2002). (Pubitemid 35006066)
67. Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin. Cancer. Res. 13, 2216-2225 (2007). (Pubitemid 46656008)
68. Heimbrook DC, Murray RE, Egeberg KD, Sligar SG, Nee MW, Bruice TC. Demethylation of N,N-dimethylaniline and p-cyano-N,N-dimethylaniline and their N-oxides by cytochromes P450LM2 and P450cam. J. Am. Chem. Soc. 106, 1514-1515 (1984).
69. Seto Y, Guengerich FP. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J. Biol. Chem. 268, 9986-9997 (1993). (Pubitemid 23150172)
70. Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiation Oncol. Biol. Phys. 42, 763-767 (1998). (Pubitemid 28559413)
71. Yakkundi A, McErlane V, Murray M et al. Tumour selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Therapy 13, 598-605 (2006).
72. Nishida CR, Lee M, Ortiz de Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol. Pharmacol. 78, 497-502 (2010).
73. Duan J, Jiao H, Kaizerman J et al. Potent and highly selective hypoxia-activated achiral phosphoroamidate mustards as anticancer drugs. J. Med. Chem. 51, 2412-2420 (2008). (Pubitemid 351628502)
74. Hadley WM. A Review of the Literature on Enzymatic Reduction of Nitrocompounds. Inhalation Toxicology Research Institute, Lovelace Biomedical and Environmental Research Institute. Springfield, VA, USA, 1-20 (1983).
75. Spain JC. Biodegradation of nitroaromatic compounds. Annu. Rev. Microbiol. 49, 523-555 (1995).
76. Patterson AV, Ferry DM, Edmunds SJ et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 13, 3922-3932 (2007). (Pubitemid 47037600)
77. Singleton RS, Guise CP, Ferry DM et al. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res. 69, 3884-3891 (2009).
78. Guise CP, Abbattista MR, Singleton RS et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70, 1573-1584 (2010).
79. Dansette PM, Libraire J, Bertho G, Mansuy D. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem. Res. Toxicol. 22, 369-373 (2009).
80. Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92-99 (2010).
81. Bouman HJ, Schömig E, van Werkum JW et al. Paraosonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
82. Dansette PM, Rosi J, Bertho G, Mansuy D. Paraoxonase-1 and clopidogrel efficacy. Nat. Med. 17(9), 1040-1041 (2011).
83. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem. Res. Tox. 25, 348-356. (2012).
84. Bouman HJ, Schömig E, van Werkum JW et al. Reply to: 'Paraoxonase-1 and clopidogrel efficacy'. Nat. Med. 17(9), 1042-1044 (2011).
85. Dansette PM, Rosi J, Devernardi J, Bertho G, Mansuy D. Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring. Chem. Res. Toxicol. 25, 1058-1065 (2012).
86. Hagihara K, Kazui M, Kurihara A et al. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab. Dispos. 38, 898-904 (2010).
87. Dansette PM, Thébault S, Bertho G, Mansuy D. Formation and fate of a sulfenic acid intermediate in metabolic activation of the antithrombotic prodrug prasugrel. Chem. Res. Toxicol. 23, 1268-1274 (2010).
88. Shan J, Zhang B, Zhu Y et al. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J. Med. Chem. 55, 3342-3352 (2012).
89. Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung KA, Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64, 2315-2343 (2004). (Pubitemid 39388606)
90. Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR. Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14, 327-337 (1984). (Pubitemid 14108125)
91. Turpeinen M, Hofmann U, Klein K, Mürder T, Schwab M, Zanger UM. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab. Dispos. 37, 1017-1024 (2009).
92. Wang MZ, Saulter JY, Usuki E et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis- O-methylamidoxime]. Drug Metab. Dispos. 34, 1985-1994 (2006). (Pubitemid 44837759)
93. Wang MZ, Wu JQ, Bridges AS et al. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab. Dispos. 35, 2067-2075 (2007). (Pubitemid 350005197)
94. Saulter JY, Kurian JR, Trepanier LA et al. Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab. Dispos. 33, 1886-1893 (2005). (Pubitemid 41697275)
95. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 48, 617-637 (1994).
96. Yumibe N, Huie K, Chen K, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51, 165-172 (1996).
97. Berthon B, Taudou G, Combettes L et al. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem. Pharmacol. 47, 789-794 (1994).
98. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin. Exper. Allergy 29(Suppl. 3), 116-124 (1999). (Pubitemid 29333345)
99. Timmermans PB, Carini JD, Chiu AT et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am. J. Hypertens. 4, 275S-281S (1991).
100. Wong PC, Price WA Jr, Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Therap. 255, 211-217 (1990). (Pubitemid 20361505)
101. Stearns RA, Miller RR, Doss GA et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab. Dispos. 20, 281-287 (1992).
102. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207-215 (1995).
103. Iwamura A, Fukami T, Hosomi H, Nakaajima M, Yokoi T. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug. Metab. Dispos. 39, 838-846 (2011).
104. Reddy KR, Matelich MC, Ugarkar BG et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 51, 666-676 (2008). (Pubitemid 351252295)
105. Lin C, Fang C, Benetton S, Xu G, Yeh L. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob. Agents Chemother. 50, 2926-2931 (2006). (Pubitemid 44396394)